

**Evaluation Of GALECTIN-3 As An  
Inflammatory Marker In HCV Positive Patients  
With And Without Chronic Kidney Disease**

Thesis

Submitted For partial fulfillment of master degree in  
internal medicine

**BY**

**Ahmed Fouad Anwar Ismail**

M.B.B.ch (2006)

Kasr Elaini - Cairo University

**Supervised by**

**Prof.Dr. Hany Ali Refaat**

Professor of Internal Medicine and Nephrology  
Faculty of Medicine Ain Shams University

**Dr. Amr Mohamed Mohab**

Lecturer of Internal Medicine and Nephrology  
Faculty of medicine Ain Shams University

**Faculty of Medicine, Ain Shams University**

**2015**

# CONTENTS

|   | Page |
|---|------|
| ➤ Acknowledgment.....                               | I    |
| ➤ List of Abbreviations.....                        | II   |
| ➤ List of Tables.....                               | V    |
| ➤ List of Figures.....                              | VII  |
| ➤ Introduction and Aim of Work.....                 | 1    |
| ➤ Review of Literature                              |      |
| ❖ Chapter 1: Inflammation in hepatitis C            | 9    |
| ❖ Chapter 2: Inflammation in chronic kidney disease | 31   |
| ❖ Chapter 3: inflammation in hemodialysis           | 61   |
| ❖ Chapter 4: Galectin-3                             | 76   |
| ➤ Patients and Methods.....                         | 98   |
| ➤ Results.....                                      | 106  |
| ➤ Discussion.....                                   | 126  |
| ➤ Summary.....                                      | 134  |
| ➤ Conclusion.....                                   | 140  |
| ➤ Recommendations.....                              | 141  |
| ➤ References.....                                   | 142  |
| ➤ Arabic Summary.....                               |      |

# ***Acknowledgment***

*First and foremost, I thank “**God**” the Most Gracious, the Most Merciful for granting me the power to proceed and accomplish this work.*

*I would like to express my deepest gratitude and great appreciation to **Dr. Hany Refaat**, Professor of Internal Medicine and Nephrology, Faculty of Medicine – Ain Shams University, for giving me the honor of working under his supervision and providing me with lot of encouragement and guidance throughout this work.*

*I would like to acknowledge my profound gratitude to **Dr.Amr Mohab**, Lecturer of internal medicine and Nephrology, Faculty of Medicine Ain Sham University, for his continuous support, help and generous instructions throughout this work in order to be accomplished in this form*

*My **wife** for the great support and patience.*

*Finally, I would like to dedicate this work to **my parents** for their great care, support and encouragement along this work and throughout my life.*

## **List of Abbreviations**

|   |              |                                       |
|---|--------------|---------------------------------------|
| • | Aa           | Aminoacids                            |
| • | AGE          | Advancedglycationendproduct;          |
| • | AKI          | Acute kidney injury                   |
| • | ALE          | Advanced lipoxidationendproduct.      |
| • | AUC          | Area under curve                      |
| • | AVG          | Arteriovenous grafts                  |
| • | bvdv         | Bovine viral diarrhea virus           |
| • | C.pneumoniae | Chlamydia pneumoniae                  |
| • | C1           | Complement 1                          |
| • | C3           | Complement 3                          |
| • | C4           | Complement 4                          |
| • | CHC          | Chronic hepatitis c                   |
| • | CKD          | Chronic kidney disease                |
| • | CML          | Nε-carboxymethyllysine                |
| • | CRD          | Carbohydrate recognition domain       |
| • | CRH          | Corticotropin releasing hormone       |
| • | CRP          | C -reactive protein                   |
| • | CSFV         | Classic swine fever virus             |
| • | CTL          | Cytotoxic T lymphocytes               |
| • | CVD          | Cardiovascular diseases               |
| • | DcR3         | Decoy receptor 3                      |
| • | Denv-1       | Dengue virus 1                        |
| • | Denv-2       | Dengue virus 2                        |
| • | EMT          | Epithelial to mesenchymal transition  |
| • | EPO          | Erythropoietin                        |
| • | ERK          | Extracellular signal-regulated kinase |
| • | ESRD         | End stage renal disease               |
| • | FCR          | Fractional catabolic rate             |
| • | GFR          | Glomerular filtration rate            |
| • | GM-CT-01     | Galactomannan                         |
| • | GR-MD-02     | Galactoarabino-rhamnogalaturonan      |
| • | HCC          | Hepatocellular carcinoma              |

|   |                |   |
|---|----------------|---|
| • | HCV            | Hepatitis c virus                             |
| • | HD             | Hemodialysis                                  |
| • | HDL            | High density lipoprotein                      |
| • | HFD            | High fat diet                                 |
| • | HIV            | Human immunodeficiency virus                  |
| • | HLA            | Human leuckocyte antigen                      |
| • | ho-1           | Heme-oxygenase-1                              |
| • | HSC            | Hepatic satellatecellss                       |
| • | Hs-CRP         | High Sensitive CRP                            |
| • | IBD            | Inflammatory Bowel Disease                    |
| • | Icam-1         | Intercellular Adhesion molecule 1             |
| • | IFN- $\gamma$  | Interferon- $\gamma$                          |
| • | IgA            | Immunoglobulin A                              |
| • | igf-1          | Insuline like growth factor 1                 |
| • | IgG            | Immunoglobulin G                              |
| • | IL             | Interleukin                                   |
| • | IL-1           | Interleukin-1                                 |
| • | IL-10          | Interleukin-10                                |
| • | IL-1 $\beta$   | Interleukin-1 $\beta$                         |
| • | IL-6R $\alpha$ | Interleukin-6 receptor alpha                  |
| • | IL-8           | Interleukin-8                                 |
| • | IRS-1          | Insulin receptor substrate-1                  |
| • | JEV            | Japanese encephalitis virus                   |
| • | KDW            | Kidney disease wasting                        |
| • | KCs            | Kupffer cells                                 |
| • | KDIGO          | Kidney disease improving global outcomes      |
| • | LDL            | Low densietylipoprotien                       |
| • | LPS            | Lipopolysaccaride                             |
| • | LSECs          | Liver sinusoidal endothelial cells;           |
| • | M1             | Activated macrophage                          |
| • | Mcp-1          | monocyte chemotactic protein-1                |
| • | MIP            | Macrophage inflammatory protein               |
| • | NASH           | Non –alcoholic steatohepatitis                |
| • | NK             | Natural Killer Cells                          |
| • | Pecam-1        | Platelet endothelial cell adhesion molecule-1 |

- PGE2 Prostaglandin E2
- PTX3 Pentraxin 3
- RAGE Receptor for AGEs
- ROS Reactive oxygen species.
- SAA Serum amyloid A
- SAP Serum amyloid protein
- SLE Systemic lupus erythematosus
- Tgf- $\beta$  Transforming growth factor beta
- TH-1 T-helper 1
- TNF-  $\alpha$  Tumor necrosis factor alpha
- TSAT Serum ferritin and transferrin saturation
- UUU Unilateral uritic obstruction
- VAT Visceral Adipose Tissue
- Vcam-1 Vascular Cell Adhesion Molecule-1
- VWF Von Willebrand Factor
- WHO World Health Organization
- WNV West Nile Virus
- YFV Yellow fever virus

## ***List of Tables***

| <b>Table No.</b> | <b>Title</b>   | <b>Page No.</b> |
|------------------|--|-----------------|
| 1.               | Induction of chemical mediators in liver cells populations during liver inflammation | 24              |
| 2.               | Inflammatory markers that have been studied in patients with CKD                     | 35              |
| 3.               | Interpretation of serum CRP levels and atherosclerotic cardiovascular diseases       | 42              |
| 4.               | List of Galactins and their original names   | 77              |
| 5.               | Distribution of the studied subjects collectively as regard to general data          | 106             |
| 6.               | Laboratory results of the studied patients collectively                              | 108             |
| 7.               | Kidney function test among all the studied groups                                    | 109             |
| 8.               | C- reactive protein and Galectin-3 among studied groups collectively                 | 110             |
| 9.               | Distribution of the studied groups as regards general data                           | 111             |
| 10               | Basic laboratory characteristics among the studied groups                            | 112             |
| 11               | Kidney function test among the studied groups  | 115             |
| 12               | C- reactive protein and Galectin-3 among studied groups                              | 116             |
| 13.              | Correlation between serum Galectin-3 and other parameters in Group 1                 | 118             |
| 14.              | Correlation between serum Galectin-3 and other parameters in Group 2                 | 119             |

|     |  |     |
|-----|--|-----|
| 15. | Correlation between serum Galectin-3 and other parameters in Group 3                                       | 121 |
| 16. | Sensitivity and Specificity for CRP & Galectin-3 for differentiating between HCV positive and HCV negative | 124 |



## **List of Figures**

| <b>Figure No.</b> | <b>Title</b>  | <b>Page No.</b> |
|-------------------|---|-----------------|
| 1.                | The family Flaviviridae.  | 9               |
| 2.                | Scheme of sinusoidal structure in normal liver and in liver inflammation .            | 25              |
| 3.                | Kinetic of acute-phase protein production.  | 45              |
| 4.                | Mechanism of trans-signalling   | 48              |
| 5.                | Schematic representation of the structure of different members of the galectin family | 79              |
| 6.                | Classes of galactin family  | 81              |
| 7.                | Galectin-3 structure and function   | 84              |
| 8.                | Galectin-3 ablation and renal, vascular and liver disease in metabolic disorders.     | 94              |
| 9                 | Age distribustion among the study   | 107             |
| 10                | Distribution of the studied groups as regards to age per years                        | 111             |
| 11                | Distribution of the studied groups as regard to gender                                | 112             |
| 12                | Hb among the studied groups   | 114             |

|    |  |     |
|----|--|-----|
| 13 | Serum Albumin among the studied groups                           | 114 |
| 14 | Distribution of the studied groups in regard to serum creatinine | 115 |
| 15 | eGFR in relation to the studied groups                           | 116 |
| 16 | CRP among the studied groups                                     | 117 |
| 17 | Serum Galectin 3 level among the studied groups                  | 117 |
| 18 | Relation between Serum Galectin 3 and CRP                        | 120 |
| 19 | Relation between serum Galectin 3 and eGFR                       | 122 |
| 20 | Relation between serum Galectin 3 and serum creatinine           | 122 |
| 21 | Relation between serum Galectin 3 and CRP                        | 123 |

# **INTRODUCTION**

It is estimated that 3-4 million people are infected with HCV each year. 130-170 million people are chronically infected with HCV and at risk of developing liver cirrhosis and/or liver cancer. More than 350,000 people die from HCV-related liver diseases each year (*WHO, 2012*).

HCV infection is found worldwide. Countries with high rates of chronic infection are Egypt (14.7 %) (*Egypt Demographic and Health Survey, 2008*), Pakistan (4.8%) and China (3.2%) (*WHO, 2012*).

Egypt has a very high prevalence of HCV and a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma (*Lehman and Wilson, 2009*).

Liver fibrosis is defined as an abnormal accumulation of extracellular matrix in the liver. Its endpoint is liver cirrhosis which is responsible for a significant morbidity

and mortality. Cirrhosis is an advanced stage of fibrosis, characterised by formation of regenerative nodules of liver parenchyma separated by fibrotic septa, which result from cell death, aberrant extracellular matrix deposition and vascular reorganisation. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation (*Saile B et.al,2007 and Ramadori G et.al,2004*) .

Removing the insult and stopping the persistent inflammatory stimuli is probably the best way to prevent progression of fibrosis; this has been shown in many patients with chronic hepatitis C and in smaller numbers of patients with autoimmune hepatitis. Clinical data confirmed that, providing appropriate, targeted treatment to patients with histologically advanced liver disease, especially those with autoimmune hepatitis, may improve their long-term outcome (*Malekzadeh R et.al, 2004*) .

Nevertheless, prevention of the progression of fibrosis to cirrhosis remains the major clinical goal. The poor prognosis of cirrhosis is aggravated by the frequent occurrence of hepatocellular carcinoma (*Saile B*

*et.al,2007*) .Inflammation is a key factor in the initiation and maintenance of fibrotic processes within the liver (*Karlmark et al., 2008*).

Hepatitis C virus (HCV) is also associated with a wide spectrum of clinical and biological extrahepatic manifestations ,In chronically infected patients, the virus can trigger an impairment in lymphoproliferation with cryoglobulin production (*Zignego AL et.al,2007*).

Mixed cryoglobulinemia with its complications (skin, neurological, renal, and rheumatologic) is the most significant extrahepatic manifestation of HCV infection (*Stefanova-Petrova et.al, 2007*) .

In addition to the risk of renal disease progression, the overall prognosis for patients with HCV-related nephritis is poor because of the high incidence of co-infections and associated cardiovascular disease. A retrospective cohort study involving more than 470,000 adult veterans showed that patients with HCV infection were more likely to develop end stage renal disease (4.3 per 1000 person-year) than HCV-seronegative patients (3.1 per 1000 person-year). A cross-sectional study showed that

HCV-infected patients had a 40% higher likelihood for developing renal insufficiency—defined as serum creatinine levels greater than or equal to 1.5 mg/dL—compared with seronegative subjects (*Chadban SJ et.al,2005*) .

Chronic kidney disease (CKD) represents a significant global health problem with few therapeutic options currently known to slow its progression. The prevalence of moderate to advanced stages of CKD has increased by an alarming 42% over the past decade (*Okamura DM et.al,2011*).

Progressive renal disease is the consequence of expansion of interstitial extracellular matrix which leads to nephron loss. Two critical pathways have a significant impact in renal injury; tubular apoptosis and defective tissue remodeling characterized by the imbalance between matrix synthesis and matrix degradation (*Li Y et.al,2009*).

Renal tubular cell apoptosis and subsequent tubular atrophy are an important cause of progressive loss of kidney functional decline. Apoptosis is the end result of a

complex regulatory system balancing survival factors and cell activation/injury signals (*Zhang G et.al,2003*) .

Apoptosis occurs principally through two separate yet interlinked signaling mechanisms: the extrinsic pathway, activated by pro-apoptotic receptor signals at the cell surface, and the intrinsic pathway, activated by mitochondrial signals from within the cell. (*Zhang G et.al,2003 and Kang EH et.al,2009*).

During the final phases of classical repair of the tubular cell injury, extracellular matrix synthesis and degradation reach equilibrium, and normal tissue architecture is restored. By contrast, in progressive kidney disease, this final phase is altered and the normal architecture is irreversibly damaged (*Zhang G et.al,2003 and Kang EH et.al,2009*).

Lectins are carbohydrate-binding proteins that have an affinity for specific oligosaccharides (*Ostalska-Nowicka D et.al,2009*) .

Galectins are low molecular weight, calcium-independent,  $\beta$ -galactoside-binding lectins. Galectin-3